Integrating Novel Lipid-Lowering Therapies and Addressing Cardiovascular Care Costs

In this episode, Integrating Novel Lipid-Lowering Therapies and Addressing Cardiovascular Care Costs, the panelists explore the following questions:

Another PCSK9 inhibitor, enlicitide, is under investigation as a pill. If approved, how do you see this therapy fitting into treatment algorithms?

What are the projections for the economic burden of cardiovascular disease in the upcoming years and how does this underscore the need for more cost-effective care?

The experts examined enlicitide, an oral PCSK9 inhibitor currently under investigation, which could offer a convenient alternative to injectable therapies and may be incorporated into treatment algorithms for patients who are statin-intolerant or require additional LDL-C lowering. Its oral formulation may improve adherence compared with injectable PCSK9 inhibitors, though real-world data will be needed to confirm this. Projections indicate that the economic burden of cardiovascular disease will continue to rise due to an aging population and increasing prevalence of risk factors. These trends underscore the urgent need for cost-effective therapies and care models that optimize adherence, outcomes, and resource utilization across the healthcare system.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, Facilitating Access to Non-Statin LDL-C Lowering Therapies, features the panelists advancing their conversation on the role of healthcare providers in helping patients navigate access to non-statin LDL-C–lowering therapies, including institutional approaches to standardizing support. It also explores the benefits and limitations of Medicare Part B and Part D coverage for these therapies and how coverage considerations impact treatment decisions.